GO:1900272 negative regulation of long-term synaptic potentiation: Molecular Brakes, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1900272 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of long-term synaptic potentiation (LTP), a cellular correlate of learning and memory.
• Negative regulation of LTP is essential for synaptic homeostasis, preventing runaway excitation and preserving information storage capacity in hippocampal circuits.
• Key molecular players include microRNAs, Rac GTPase-activating proteins (BCR and ABR), the PI3K regulatory subunit p85α, TORC1, Arc/Arg3.1, and Mdm2-p53 signaling.
• Dysregulation of LTP restraint mechanisms is linked to cognitive disorders, neurodegeneration, and aberrant synaptic plasticity.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable causal dissection of negative regulators of LTP.
• EDITGENE provides end-to-end CRISPR cell model and library screening services to accelerate research on GO:1900272-related genes.
Description
Long-term synaptic potentiation (LTP) is a persistent strengthening of synaptic transmission widely studied as a cellular substrate of learning and memory. However, unopposed LTP would saturate neural circuits and degrade information storage, so neurons deploy active braking mechanisms collectively annotated under the Gene Ontology term GO:1900272, negative regulation of long-term synaptic potentiation. This biological process encompasses any molecular event that stops, prevents, or reduces the frequency, rate, or extent of LTP. Understanding these brakes is critical because their failure contributes to pathological excitability, cognitive decline, and neurodevelopmental disorders. Research over the past two decades has identified diverse negative regulators, including activity-induced microRNAs, Rac GTPase-activating proteins, phosphoinositide 3-kinase (PI3K) subunits, TORC1 components, and the immediate-early protein Arc/Arg3.1. These molecules act at distinct stages of LTP, from induction to maintenance, and their coordinated action ensures synaptic homeostasis. For researchers, GO:1900272 provides a structured framework to interrogate how specific genes constrain plasticity, with direct implications for drug target discovery and disease modeling.
negative regulation of long-term synaptic potentiation At A Glance
| GO ID | GO:1900272 |
|---|---|
| GO term | negative regulation of long-term synaptic potentiation |
| Ontology | biological_process |
| Synonym | down regulation of LTP; inhibition of LTP; negative regulation of long-term potentiation |
| Major function | Suppression or dampening of LTP induction, expression, or maintenance |
| Related processes | Synaptic plasticity, homeostatic synaptic downscaling, memory consolidation |
| Cellular context | Hippocampal neurons, dendritic spines, postsynaptic density |
| Key molecular players | MicroRNAs, Rac GTPase-activating proteins, PI3K p85α, TORC1, Arc/Arg3.1, Mdm2-p53 |
What Is GO:1900272?
GO:1900272, negative regulation of long-term synaptic potentiation, is defined by QuickGO as any process that stops, prevents, or reduces the frequency, rate, or extent of long-term synaptic potentiation. In practical terms, it covers molecular and cellular events that actively suppress the induction, expression, or maintenance of LTP, including downregulation of LTP, inhibition of LTP, and related synonyms. This term is a biological process and is distinct from positive regulation of LTP or from LTP itself.
Why Is negative regulation of long-term synaptic potentiation Important in Cell Biology?
Negative regulation of LTP is fundamental to neural circuit stability and cognitive function. Without active braking, LTP would saturate synapses, impairing the contrast needed for memory encoding and predisposing neurons to excitotoxicity. This process is also a convergence point for signaling pathways that integrate developmental cues, stress responses, and metabolic state. Dysregulation of LTP restraint has been implicated in cognitive disorders, neurodegeneration, and aberrant plasticity, making its components attractive targets for therapeutic intervention.
• Prevents synaptic saturation and preserves information storage capacity in hippocampal circuits.
• Maintains excitation-inhibition balance and protects against excitotoxicity.
• Integrates microRNA-mediated post-transcriptional control of plasticity-related genes.
• Involves Rac GTPase-activating proteins BCR and ABR that constrain Rac1 activity during LTP maintenance.
• Requires PI3K p85α-dependent cofilin recruitment and actin polymerization for proper spine remodeling.
• TORC1 signaling is required for late-phase LTP, and its negative regulation contributes to plasticity set-points.
• Arc/Arg3.1 mediates membrane remodeling and homeostatic downscaling that opposes LTP.
• Mdm2-dependent regulation of p53 expression during LTP provides a nuclear brake on plasticity.
• Dysregulation is linked to cognitive decline and neurodegenerative conditions.
• Provides a rich target space for CRISPR-based functional genomics and drug discovery.
What Happens During negative regulation of long-term synaptic potentiation?
Induction-phase braking by microRNAs
In simple terms: Tiny RNA molecules quickly put the brakes on the early signals that would otherwise strengthen synapses.
Following LTP induction in vivo, rapid changes in microRNA expression occur, and these plasticity-related microRNAs can suppress the translation of proteins required for LTP maintenance, thereby acting as negative regulators. This microRNA-mediated restraint provides a fast, reversible layer of control over synaptic strengthening.
Rac1 GTPase inactivation by BCR and ABR
In simple terms: Two related proteins switch off a molecular toggle called Rac1, which is needed to keep synapses strengthened.
BCR and ABR are Rac GTPase-activating proteins that regulate synaptic Rac1 activity. Their action limits Rac1-dependent signaling required for LTP maintenance, and loss of these proteins alters LTP maintenance and learning and memory, demonstrating their role in negative regulation of LTP.
PI3K p85α-dependent actin remodeling
In simple terms: A lipid kinase subunit helps reorganize the structural skeleton of dendritic spines, which can restrain synaptic potentiation.
The PI3K regulatory subunit p85α couples LTP with cofilin recruitment and actin polymerization in dendritic spines. This cytoskeletal remodeling is essential for proper spine morphology and can serve as a negative feedback mechanism that limits excessive potentiation.
TORC1 and late-phase LTP control
In simple terms: A nutrient-sensing kinase complex sets a threshold for how much late, protein-synthesis-dependent strengthening can occur.
TORC1 is required for late-phase LTP in the hippocampus. Negative regulation of TORC1 signaling therefore constrains the persistence of LTP, and perturbations in this pathway affect long-lasting synaptic changes.
Arc/Arg3.1-mediated membrane remodeling and homeostatic downscaling
In simple terms: An activity-induced protein reshapes membranes and weakens synapses to balance overall activity.
Arc/Arg3.1 is an immediate-early gene product that mediates membrane remodeling and is a key effector of homeostatic synaptic downscaling, a process that opposes LTP and helps maintain network stability. Its action represents a negative regulatory arm of plasticity.
Mdm2-p53 nuclear signaling
In simple terms: A tumor-suppressor pathway in the nucleus puts a brake on gene expression programs that support long-lasting synaptic changes.
Mdm2-dependent regulation of p53 expression occurs during LTP, and this axis can limit the transcriptional output needed for LTP maintenance, thereby contributing to negative regulation of LTP.
Key Genes Involved in GO:1900272 negative regulation of long-term synaptic potentiation
The following genes and proteins have been experimentally linked to negative regulation of long-term synaptic potentiation, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| BCR | Rac GTPase-activating protein; limits Rac1 activity | Regulates LTP maintenance and learning/memory |
| ABR | Rac GTPase-activating protein; limits Rac1 activity | Regulates LTP maintenance and learning/memory |
| PIK3R1 (p85α) | PI3K regulatory subunit; couples LTP to actin remodeling | Controls cofilin recruitment and spine morphology |
| TORC1 components (e.g., MTOR, RPTOR) | Kinase complex required for late-phase LTP | Sets threshold for persistent synaptic strengthening |
| ARC (Arc/Arg3.1) | Immediate-early protein; membrane remodeling | Mediates homeostatic synaptic downscaling |
| MDM2 | E3 ubiquitin ligase; regulates p53 | Modulates p53 expression during LTP |
| TP53 | Tumor suppressor; transcription factor | Target of Mdm2 during LTP; potential brake on plasticity |
| miR-132 | Activity-regulated microRNA | Rapidly regulated after LTP induction; modulates plasticity |
| miR-134 | Activity-regulated microRNA | Regulates spine morphology and LTP maintenance |
| miR-124 | Neuron-enriched microRNA | Contributes to plasticity-related microRNA networks |
| miR-9 | Activity-regulated microRNA | Potential negative regulator of LTP-related translation |
| miR-137 | Neuron-enriched microRNA | Linked to synaptic plasticity and cognitive disorders |
| miR-181a | Activity-regulated microRNA | Modulates plasticity-related gene expression |
| miR-146a | Immune-related microRNA | May influence synaptic plasticity under inflammatory conditions |
| miR-26a | Activity-regulated microRNA | Potential regulator of LTP maintenance |
| miR-29a | Activity-regulated microRNA | Associated with synaptic plasticity and memory |
| miR-218 | Neuron-enriched microRNA | Regulates dendritic spine development and plasticity |
How Is negative regulation of long-term synaptic potentiation Regulated?
Negative regulation of LTP is itself tightly regulated at multiple levels. MicroRNAs provide rapid post-transcriptional control, with specific species up- or downregulated within minutes to hours after LTP induction. Rac GTPase-activating proteins BCR and ABR set the threshold for Rac1 activation, and their own activity can be modulated by upstream signals. PI3K p85α links receptor tyrosine kinase signaling to actin dynamics, and its availability or phosphorylation state influences the extent of spine remodeling. TORC1 activity is governed by nutrient and energy status, integrating metabolic cues into plasticity set-points. Arc/Arg3.1 expression is driven by activity and feeds back to dampen synaptic strength through membrane trafficking and receptor endocytosis. Finally, the Mdm2-p53 axis provides a nuclear checkpoint that can be engaged by stress or DNA damage signals to limit plasticity-related transcription.
negative regulation of long-term synaptic potentiation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ARC | Alzheimer's disease; homeostatic downscaling deficits | Arc knockout or overexpression in hippocampal neurons |
| BCR/ABR | Epilepsy; excitability disorders | BCR/ABR double knockout mouse or iPSC-derived neurons |
| PIK3R1 | Cognitive disorders; actin remodeling defects | p85α point mutant knock-in in neuronal cell lines |
| MDM2/TP53 | Neurodegeneration; stress responses | Mdm2 conditional knockout or p53 knock-in |
| miR-134 | Psychiatric disorders; spine morphology | miR-134 knockout or sponge overexpression |
Cognitive disorders and neurodegeneration
Impaired negative regulation of LTP can lead to synaptic saturation and excitotoxicity, which are implicated in cognitive decline and neurodegenerative conditions. Homeostatic synaptic downscaling, mediated in part by Arc/Arg3.1, is disrupted in models of Alzheimer's disease and other dementias, suggesting that failure of LTP brakes contributes to disease pathogenesis.
Neurodevelopmental and psychiatric disorders
Dysregulated microRNA networks that normally restrain LTP have been associated with neurodevelopmental and psychiatric disorders, including schizophrenia and autism spectrum disorders. Altered expression of plasticity-related microRNAs can shift the balance between potentiation and depression, affecting circuit function.
Epilepsy and excitability disorders
Loss of negative regulation of LTP may contribute to hyperexcitability and seizure susceptibility. Rac1 overactivation, when unchecked by BCR/ABR, can promote aberrant plasticity and network instability, providing a mechanistic link to epilepsy.
Cancer and cell growth signaling
While primarily studied in neurons, components such as PI3K p85α and Mdm2-p53 are also central to cancer biology. Their dual roles in plasticity and proliferation highlight potential crosstalk and the need for tissue-specific targeting.
From negative regulation of long-term synaptic potentiation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is BCR/ABR required for LTP maintenance restraint? | BCR/ABR double knockout in hippocampal neurons |
| Does p85α phosphorylation regulate actin remodeling? | Point mutation knock-in of PIK3R1 phospho-sites |
| What is the role of Arc/Arg3.1 in homeostatic downscaling? | Arc knockout and tagged knock-in for live imaging |
| How does Mdm2 regulate p53 during LTP? | Mdm2 conditional knockout or p53 overexpression |
| Which microRNAs negatively regulate LTP? | MicroRNA knockout or overexpression libraries |
| Does TORC1 inhibition block late-phase LTP? | Raptor knockout or rapamycin treatment |
How to Study the negative regulation of long-term synaptic potentiation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Field electrophysiology | LTP magnitude and maintenance | Hippocampal slice recordings |
| Patch-clamp | Synaptic currents and plasticity | Single-cell analysis of LTP |
| Confocal imaging | Spine density and morphology | Structural plasticity studies |
| Small RNA-seq | MicroRNA expression changes | Activity-dependent microRNA profiling |
| Phosphoproteomics | Kinase signaling changes | PI3K/TORC1 pathway analysis |
| Western blot | Protein expression and phosphorylation | Validation of candidate regulators |
| Luciferase reporter | MicroRNA target validation | 3'UTR binding assays |
| CRISPR screening | Gene function in plasticity | Pooled knockout screens |
Electrophysiology
Field and whole-cell patch-clamp recordings in hippocampal slices are the gold standard for measuring LTP and its negative regulation. Paired-pulse ratios, input-output curves, and maintenance phase recordings can reveal deficits or enhancements in plasticity.
Imaging and spine morphometry
Two-photon or confocal imaging of dendritic spines in GFP-labeled neurons allows quantification of spine density, size, and shape changes associated with LTP and its restraint. Live imaging of tagged Arc/Arg3.1 can track membrane remodeling dynamics.
Transcriptomics and small RNA sequencing
RNA-seq and small RNA-seq after LTP induction identify activity-dependent changes in mRNAs and microRNAs that contribute to negative regulation. These datasets can nominate candidate brakes for functional validation.
Proteomics and phosphoproteomics
Mass spectrometry-based proteomics can quantify changes in synaptic protein abundance and phosphorylation following LTP, revealing signaling nodes such as PI3K, TORC1, and Mdm2-p53 that mediate negative regulation.
How CRISPR Can Be Used to Study GO:1900272 negative regulation of long-term synaptic potentiation
Knockout
CRISPR knockout of candidate negative regulators such as BCR, ABR, or Arc allows direct testing of their requirement for restraining LTP. Loss-of-function models can be generated in hippocampal cell lines or primary neurons, followed by electrophysiology to quantify plasticity changes.
Point Mutation
Point mutations in genes like PIK3R1 can dissect phospho-dependent interactions that mediate negative regulation. CRISPR-mediated knock-in of specific phospho-dead or phospho-mimetic alleles enables precise structure-function analysis.
Knock-in
Knock-in of tagged alleles, such as Arc-GFP or Mdm2-FLAG, facilitates live imaging and biochemical isolation of protein complexes during LTP. These models preserve endogenous regulation while enabling tracking.
Overexpression
Overexpression of microRNAs or negative regulators like Mdm2 can enhance LTP braking and reveal dosage-sensitive effects. CRISPR activation (CRISPRa) or lentiviral overexpression can be used to test sufficiency.
How EDITGENE Supports negative regulation of long-term synaptic potentiation Research
Researchers studying negative regulation of long-term synaptic potentiation-related genes often need to determine whether a candidate gene is causally involved in restraining LTP or merely correlated with activity changes. This requires precise genetic models that can isolate gene function in relevant neuronal contexts.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of long-term synaptic potentiation research.
Frequently Asked Questions About negative regulation of long-term synaptic potentiation
What is GO:1900272?
GO:1900272 is the Gene Ontology term for negative regulation of long-term synaptic potentiation, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of LTP.
What genes are involved in negative regulation of long-term synaptic potentiation?
Key genes include BCR, ABR, PIK3R1, MTOR, ARC, MDM2, TP53, and several microRNAs such as miR-132 and miR-134.
How does Arc/Arg3.1 negatively regulate LTP?
Arc/Arg3.1 mediates membrane remodeling and homeostatic synaptic downscaling, which weakens synapses and opposes LTP.
What is the role of Rac1 in LTP restraint?
Rac1 activity is required for LTP maintenance, and its inactivation by BCR and ABR GTPase-activating proteins limits potentiation.
How do microRNAs regulate LTP?
Activity-induced microRNAs rapidly suppress translation of plasticity-related proteins, providing a fast brake on LTP induction and maintenance.
Is TORC1 involved in negative regulation of LTP?
TORC1 is required for late-phase LTP; negative regulation of TORC1 signaling constrains the persistence of synaptic strengthening.
What diseases are linked to dysregulated LTP brakes?
Cognitive disorders, neurodegeneration, epilepsy, and psychiatric conditions have been associated with impaired negative regulation of LTP.
How can I study negative regulation of LTP in the lab?
Electrophysiology, imaging, transcriptomics, proteomics, and CRISPR-based genetic models are commonly used.
What CRISPR models are available for LTP research?
Knockout, point mutation, knock-in, and overexpression models can be generated for genes such as BCR, ABR, PIK3R1, ARC, and MDM2.
Does EDITGENE provide services for LTP-related genes?
Yes, EDITGENE offers custom CRISPR cell model generation, library screening, and bioinformatics for negative regulation of LTP research.
Conclusion
GO:1900272, negative regulation of long-term synaptic potentiation, represents a critical homeostatic brake that prevents synaptic saturation and preserves cognitive function. The diverse molecular players, from microRNAs to Rac GTPase-activating proteins, PI3K subunits, TORC1, Arc/Arg3.1, and Mdm2-p53, offer a rich landscape for mechanistic and translational research. Dysregulation of these brakes is increasingly linked to neurological and psychiatric disorders, underscoring the need for precise genetic models. CRISPR-based approaches, supported by EDITGENE services, empower researchers to dissect causality and accelerate discovery in this important field.
References
- 1. Joilin G et al.. 2014. Rapid regulation of microRNA following induction of long-term potentiation in vivo.. Front Mol Neurosci 7:98 PMID: 25538559
- 2. Oh D et al.. 2010. Regulation of synaptic Rac1 activity, long-term potentiation maintenance, and learning and memory by BCR and ABR Rac GTPase-activating proteins.. J Neurosci 30(42):14134-44 PMID: 20962234
- 3. López-García S et al.. 2024. PI3K couples long-term synaptic potentiation with cofilin recruitment and actin polymerization in dendritic spines via its regulatory subunit p85α.. Cell Mol Life Sci 81(1):358 PMID: 39158722
- 4. Ryan B et al.. 2015. Plasticity-related microRNA and their potential contribution to the maintenance of long-term potentiation.. Front Mol Neurosci 8:4 PMID: 25755632
- 5. Hedde PN et al.. 2021. Membrane Remodeling by Arc/Arg3.1.. Front Mol Biosci 8:630625 PMID: 33763452
- 6. Zhou Y et al.. 2006. Requirement of TORC1 for late-phase long-term potentiation in the hippocampus.. PLoS One 1(1):e16 PMID: 17183642
- 7. Siddoway B et al.. 2014. Molecular mechanisms of homeostatic synaptic downscaling.. Neuropharmacology 78:38-44 PMID: 23911745
- 8. Lisachev PD et al.. 2015. Mdm2-dependent regulation of p53 expression during long-term potentiation.. Bull Exp Biol Med 158(3):333-5 PMID: 25573363
